NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00003424,Tamoxifen in Treating Patients With Primary Liver Cancer,https://clinicaltrials.gov/study/NCT00003424,,COMPLETED,"RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using tamoxifen may fight liver cancer by blocking the absorption of estrogen. It is not yet known whether receiving tamoxifen is more effective than no further therapy in treating patients with primary liver cancer.

PURPOSE: Randomized phase III trial to compare high-dose tamoxifen with no further treatment in treating patients with liver cancer that cannot be surgically removed.",NO,Liver Cancer,DRUG: tamoxifen citrate,,,,"National Medical Research Council (NMRC), Singapore",,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,300,OTHER_GOV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: TREATMENT,NMRC-AHCC01|CDR0000066444|EU-98018,1997-04,2000-06,2009-08,2004-08-04,,2013-06-26,"Prince of Wales Hospital, Shatin, New Territories, Hong Kong|University of Udayana, Sanglah, Denpasar, Bali, Indonesia|Universiti Kebangsaan Malaysia, Bangi, 43600, Malaysia|Wellington Cancer Centre, Wellington, 6039, New Zealand|National Cancer Institute - Karachi, Karachi, Pakistan|Nishtar Medical College, Multan, Multan, Pakistan|Tan Tock Seng Hospital, Singapore, 1130, Singapore|National Cancer Centre - Singapore, Singapore, 169608, Singapore",
